The intervention group consisted of MS patients who were either untreated or treated with a different disease-modifying therapy (DMT), such as IFN-β, glatiramer acetate, natalizumab, fingolimod, and abatacept. This evidence concerns the gene IFNB1 and myeloid sarcoma.